Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Sequestered Transscleral, Controlled-Release Celecoxib Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous

NCT04120636 is registered in ClinicalTrials.gov with Targeted Therapy Technologies, LLC as lead sponsor.

NCT NCT04120636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04120636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Sequestered Transscleral, Controlled-Release Celecoxib Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous
Lead sponsor
Targeted Therapy Technologies, LLC
Phase
Phase 1
Overall status
Unknown status
Start date
March 5, 2021
Completion date
June 30, 2024
Enrollment
3 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

branch retinal vein occlusion, central serous retinopathy with pit of optic disc, commotio retinae, epiretinal membrane, macula edema, radiation retinopathy, vitritis